According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, which means the company has less short interest than most of its peers. Did ...

Discover how personalized medicine uses genetics and data to create tailored treatments, improving outcomes in cancer, rare diseases, and more. Explore its future in healthcare.

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...